Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Onconova Therapeutics, Inc. (ONTX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results |
| 05/15/2023 |
8-K
| Quarterly results |
| 03/16/2023 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
8-K
| Quarterly results |
| 03/17/2022 |
8-K
| Quarterly results |
| 11/12/2021 |
8-K
| Quarterly results |
| 08/12/2021 |
8-K
| Quarterly results |
| 03/11/2021 |
8-K
| Quarterly results |
| 11/12/2020 |
8-K
| Quarterly results |
| 08/12/2020 |
8-K
| Quarterly results |
| 05/14/2020 |
8-K
| Quarterly results |
| 03/24/2020 |
8-K
| Quarterly results|
Docs:
|
"Onconova Therapeutics Announces Completion of Enrollment of Phase 3 INSPIRE Trial, Provides a Corporate Update, and Reports 2019 Financial Results NEWTOWN, Pa., March 24, 2020 -- Onconova Therapeutics, Inc. , a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes , today reported financial results for the year ended December 31, 2019 and provided a corporate update. “Following significant progress throughout 2019, our team’ s immediate focus remains to advance our pivotal Phase 3 INSPIRE trial to the next milestone” said Steven M. Fruchtman, M.D., President and Chief Executive Officer. “We are excited to announce the completion of the planned enrollment of 360 patients in the INSPIRE..." |
|
| 08/14/2019 |
8-K
| Quarterly results |
| 05/14/2019 |
8-K
| Quarterly results |
| 03/26/2019 |
8-K
| Quarterly results |
| 11/13/2018 |
8-K
| Quarterly results |
| 08/14/2018 |
8-K
| Quarterly results |
| 03/08/2018 |
8-K
| Quarterly results|
Docs:
|
"Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2017 Financial Results NEWTOWN, Pa., March 8, 2018 — Onconova Therapeutics, Inc. , a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes , today provided a corporate update and reported financial results for the full year ended December 31, 2017. “The recently completed year was a pivotal period for rigosertib development programs in MDS. We achieved important goals across our full pipeline, highlighted by the recently announced promising interim analysis and the advancement of the INSPIRE pivotal trial for rigosertib, our lead Phase 3 clinical candidate. With no FDA approved therapies availab..." |
|
| 11/09/2017 |
8-K
| Quarterly results|
Docs:
|
"Onconova Therapeutics, Inc. Reports Business Highlights and Third Quarter 2017 Financial Results NEWTOWN, Pa., November 9, 2017 — Onconova Therapeutics, Inc. , a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes , today provided a corporate update and reported financial results for the third quarter ended September 30, 2017. “We are getting closer to two key milestones for the INSPIRE pivotal trial for IV rigosertib in patients with higher-risk MDS. A pre-planned interim analysis is anticipated in the coming months, and encouraging recent enrollment progress for this global trial suggests full enrollment may be achieved in the first half of 2018,” said Dr. Ram..." |
|
| 08/15/2017 |
8-K
| Quarterly results |
| 05/15/2017 |
8-K
| Form 8-K - Current report |
| 03/27/2017 |
8-K
| Form 8-K - Current report |
| 11/14/2016 |
8-K
| Form 8-K - Current report |
| 08/15/2016 |
8-K
| Quarterly results|
Docs:
|
"Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2016 Financial Results NEWTOWN, PA, August 15, 2016 — Onconova Therapeutics, Inc. , a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the second quarter ended June 30, 2016. “We are encouraged by the progress of our global Phase 3 trial of our lead product candidate, rigosertib, for patients with myelodysplastic syndromes . The INSPIRE trial is actively enrolling patients in the U.S., Europe and Japan, and we have recently opened trial sites in Israel and Australia, bringing us more than two-thirds of the way to our target of approximately 135 sites worldwide. The enrollm..." |
|
| 05/11/2016 |
8-K
| Form 8-K - Current report |
| 03/28/2016 |
8-K
| Form 8-K - Current report |
| 11/12/2015 |
8-K
| Quarterly results|
Docs:
|
"Onconova Therapeutics, Inc. Reports Recent Business Highlights and Third Quarter 2015 Financial Results NEWTOWN, PA, November 11, 2015 — Onconova Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the third quarter ended September 30, 2015. “Onconova continues to advance the development of rigosertib for the unmet needs of patients with myelodysplastic syndromes ,” said Ramesh Kumar, Ph.D., President and CEO of Onconova. “Our pivotal Phase 3 INSPIRE trial is now open at multiple sites and we anticipate enrollment of the first patient shortly. This will mark an important step towards the approval of IV rigosertib as a treatment for higher-ri..." |
|
| 05/14/2015 |
8-K
| Quarterly results|
Docs:
|
"Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2015 Financial Results NEWTOWN, PA, May 14, 2015 — Onconova Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the first quarter ended March 31, 2015. “We recently submitted to FDA and EMA a clinical trial protocol for a pivotal study of IV rigosertib in patients with higher-risk myelodysplastic syndrome after failure of hypomethylating agent therapy. We look forward to completing the regulatory process and initiating the enrollment for this study in 2015, pending receipt of appropriate financing,” said Ramesh Kumar, Ph.D., President and CEO of Onconova. “In ad..." |
|
| 03/27/2015 |
8-K
| Quarterly results |
| 11/13/2014 |
8-K
| Quarterly results|
Docs:
|
"Onconova Therapeutics, Inc. Reports Third Quarter 2014 Financial and Operational Results -Nine presentations to highlight programs including rigosertib Phase 3 trial at the ASH Annual Meeting- NEWTOWN, PA, November 13, 2014 — Onconova Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the third quarter ended September 30, 2014. “Onconova continues to make progress in all of its development programs focused on myelodysplastic syndromes ,” stated Ramesh Kumar, Ph.D., President and CEO of Onconova. “We are particularly excited to present key data from our Phase 3 ONTIME trial of rigosertib in higher risk MDS patients at the American Society of..." |
|
| 08/13/2014 |
8-K
| Quarterly results|
Docs:
|
"Onconova Therapeutics, Inc. Reports Second Quarter 2014 Financial and Operational Results NEWTOWN, PA, August 13, 2014 — Onconova Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the second quarter ended June 30, 2014. “Onconova made substantial progress during the second quarter towards our highest strategic priority, the efficient development of rigosertib for patients with myelodysplastic syndromes . Top-line results from the Phase 3 ONTIME trial of rigosertib suggest a treatment benefit for those patients who do not respond to initial treatment with the current standard of care, hypomethylating agents ; these patients are referred to ..." |
|
| 05/15/2014 |
8-K
| Quarterly results|
Docs:
|
"Onconova Therapeutics, Inc. Reports First Quarter 2014 Financial and Operational Results NEWTOWN, PA, May 12, 2014 — Onconova Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the first quarter ended March 31, 2014. “Onconova remains committed to developing rigosertib for the unmet medical needs of MDS patients. We recently announced top-line results of the Phase 3 ONTIME trial in higher risk myelodysplastic syndromes and are in the process of discussing these results with regulatory authorities in the U.S. and Europe,” said Ramesh Kumar, Ph.D., President and CEO of Onconova. “In addition, we continue to advance the oral rigosertib develop..." |
|
|
|
|